Trial Profile

This is a Phase Ib/II, Prospective , Open-label, Single Center, Bayesian Adaptive Design, Umbrella Study Evaluating the Efficacy and Safety of Neo-adjuvant Therapy in Patients With Breast Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary) ; Capecitabine (Primary) ; Carboplatin (Primary) ; Dalpiciclib (Primary) ; Fulvestrant (Primary) ; Goserelin (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Pyrotinib (Primary) ; Rezvilutamide (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Carcinoma; Ductal carcinoma; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms FINEST study

19 Mar 2024 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
19 Mar 2024 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.
19 Mar 2024 Status changed from discontinued to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com